Base de dados : MEDLINE
Pesquisa : J01.897.836.750 [Categoria DeCS]
Referências encontradas : 68 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 7 ir para página                  

  1 / 68 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27719667
[Au] Autor:Berecz B; Zelenyánszki H; Pólya S; Tamás-Nyitrai C; Oszvald M
[Ad] Endereço:Deparment of Plant Physiology and Molecular Plant Biology, Eötvös Loránd University, Budapest, Hungary.
[Ti] Título:Plastid Molecular Pharming I. Production of Oral Vaccines via Plastid Transformation.
[So] Source:Mini Rev Med Chem;17(13):1292-1315, 2017.
[Is] ISSN:1875-5607
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Vaccines produced in plants have opened up new opportunities in vaccination. OBJECTIVE: Among the various categories of vaccines, the recombinant vaccine is generally regarded as the most economical and safest type because it cannot cause disease and does not require large-scale cultivation of pathogens. Due to the low cost of their cultivation, plants may represent viable alternative platforms for producing subunit vaccines. Genetic engineering of plastids is the innovation of the last three decades and has numerous benefits when compared to nuclear transformation. Due to the high level of expression, oral vaccines produced in transplastomic plants do not have to be purified as they can be consumed raw, which, therefore, reduces the cost of preparation, transportation and handling of the vaccines. Oral vaccination also excludes the risk of other infections or contaminations, while compartmentation of the plant cell provides an excellent encapsulation to the antigen within the plastid. RESULTS & CONCLUSION: Herein we review the main biotechnological and immunological aspects of the progress achieved in the field of plastid derived edible vaccines during the last decade. As there is a public debate against genetically modified crops, the advantages and limitations of oral vaccines are also discussed.
[Mh] Termos MeSH primário: Agricultura Molecular
Plastídeos/metabolismo
Vacinas/imunologia
[Mh] Termos MeSH secundário: Biotecnologia
Engenharia Genética
Seres Humanos
Plantas/metabolismo
Proteínas Recombinantes/biossíntese
Proteínas Recombinantes/genética
Proteínas Recombinantes/imunologia
Vacinas/genética
Vacinas/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Recombinant Proteins); 0 (Vaccines)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161011
[St] Status:MEDLINE
[do] DOI:10.2174/1389557516666161004161801


  2 / 68 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27719665
[Au] Autor:Bains S; Larsson P; Aronsson H
[Ad] Endereço:Department of Biological and Environmental Sciences, University of Gothenburg, Gothenburg, Sweden.
[Ti] Título:Plastid Molecular Pharming II. Production of Biopharmaceuticals by Plastid Transformation.
[So] Source:Mini Rev Med Chem;17(13):1316-1330, 2017.
[Is] ISSN:1875-5607
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Higher plants have been used in medicine throughout human history. METHOD: While traditional medicinal uses relied on compounds produced naturally by plants, recent advances have enabled the use of plant-based factories to produce diverse agents including pharmaceuticals, antibiotics, and vaccines. The genes responsible for the production of these substances can be either transiently expressed in plants or integrated into their nuclear genome or plastid genome (plastome) by genetic transformation. This review focuses on the application of plastid transformation of higher plants to produce biopharmaceuticals for human applications that are neither antibiotics nor vaccines. Plastid transformation has several advantages over nuclear transformation and represents a minimal risk of transgene contamination to the environment via pollen grains because plastid genes are in most species normally maternally inherited and thus absent from pollen. Other advantages of sitedirected plastid insertion via homologous recombination include strong gene expression due to the plastid genome's high copy number and resistance to silencing, and the ability to achieve multi-gene expression with a single insertion step. RESULTS: Compared to bacterial systems, plant-based bioreactors offer lower production costs, lower risks of human pathogen contamination, and the possibility of exploiting post-translational modification. CONCLUSION: Consequently, sustainable plant systems based on different species, plastids, and tissues could become an important source of added value in pharmaceutical production.
[Mh] Termos MeSH primário: Agricultura Molecular
Plastídeos/metabolismo
Proteínas Recombinantes/biossíntese
[Mh] Termos MeSH secundário: Proteínas Sanguíneas/genética
Proteínas Sanguíneas/metabolismo
Citocinas/genética
Citocinas/metabolismo
Seres Humanos
Peptídeos e Proteínas de Sinalização Intercelular/genética
Peptídeos e Proteínas de Sinalização Intercelular/metabolismo
Plantas/metabolismo
Proteínas Recombinantes/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Blood Proteins); 0 (Cytokines); 0 (Intercellular Signaling Peptides and Proteins); 0 (Recombinant Proteins)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161011
[St] Status:MEDLINE
[do] DOI:10.2174/1389557516666161005095722


  3 / 68 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27655251
[Au] Autor:Pniewski T; Czyz M; Wyrwa K; Bociag P; Krajewski P; Kapusta J
[Ad] Endereço:Institute of Plant Genetics, Polish Academy of Sciences, Strzeszynska 34, 60-479, Poznan, Poland. tpni@igr.poznan.pl.
[Ti] Título:Micropropagation of transgenic lettuce containing HBsAg as a method of mass-scale production of standardised plant material for biofarming purposes.
[So] Source:Plant Cell Rep;36(1):49-60, 2017 Jan.
[Is] ISSN:1432-203X
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:KEY MESSAGE: Micropropagation protocol of transgenic lettuce bearing S-, M- and L-HBsAg was developed for increased production of uniformised material for oral vaccine preparation. Effective manufacturing of plant-based biopharmaceuticals, including oral vaccines, depends on sufficient content of a protein of interest in the initial material and its efficient conversion into an administrable formulation. However, stable production of plants with a uniformised antigen content is equally important for reproducible processing. This can be provided by micropropagation techniques. Here, we present a protocol for micropropagation of transgenic lettuce lines bearing HBV surface antigens: S-, M- and L-HBsAg. These were multiplied through axillary buds to avoid the risk of somaclonal variation. Micropropagation effectiveness reached 3.5-5.7 per passage, which implies potential production of up to 6600 plant clones within a maximum 5 months. Multiplication and rooting rates were statistically homogenous for most transgenic and control plants. For most lines, more than 90 % of clones obtained via in vitro micropropagation had HBsAg content as high as reference plants directly developed from seeds. Clones were also several times more uniform in HBsAg expression. Variation coefficients of HBsAg content did not exceed 10 % for approximately 40-85 % of clones, or reached a maximum 20 % for 90 % of all clones. Tissue culture did not affect total and leaf biomass yields. Seed production for clones was decreased insignificantly and did not impact progeny condition. Micropropagation facilitates a substantial increase in the production of lettuce plants with high and considerably equalised HBsAg contents. This, together with the previously reported optimisation of plant tissue processing and its long-term stability, constitutes a successive step in manufacturing of a standardised anti-HBV oral vaccine of reliable efficacy.
[Mh] Termos MeSH primário: Antígenos de Superfície da Hepatite B/metabolismo
Alface/crescimento & desenvolvimento
Alface/genética
Agricultura Molecular/métodos
Técnicas de Cultura de Tecidos/métodos
[Mh] Termos MeSH secundário: Plantas Geneticamente Modificadas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis B Surface Antigens)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170327
[Lr] Data última revisão:
170327
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160923
[St] Status:MEDLINE
[do] DOI:10.1007/s00299-016-2056-1


  4 / 68 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27618314
[Au] Autor:Webster GR; Teh AY; Ma JK
[Ad] Endereço:Molecular Immunology Unit, Institute for Infection and Immunity, St. George's University of London, SW17 0RE, London, UK.
[Ti] Título:Synthetic gene design-The rationale for codon optimization and implications for molecular pharming in plants.
[So] Source:Biotechnol Bioeng;114(3):492-502, 2017 Mar.
[Is] ISSN:1097-0290
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Degeneracy in the genetic code allows multiple codon sequences to encode the same protein. Codon usage bias in genes is the term given to the preferred use of particular synonymous codons. Synonymous codon substitutions had been regarded as "silent" as the primary structure of the protein was not affected; however, it is now accepted that synonymous substitutions can have a significant effect on heterologous protein expression. Codon optimization, the process of altering codons within the gene sequence to improve recombinant protein expression, has become widely practised. Multiple inter-linked factors affecting protein expression need to be taken into consideration when optimizing a gene sequence. Over the years, various computer programmes have been developed to aid in the gene sequence optimization process. However, as the rulebook for altering codon usage to affect protein expression is still not completely understood, it is difficult to predict which strategy, if any, will design the "optimal" gene sequence. In this review, codon usage bias and factors affecting codon selection will be discussed and the evidence for codon optimization impact will be reviewed for recombinant protein expression using plants as a case study. These developments will be relevant to all recombinant expression systems; however, molecular pharming in plants is an area which has consistently encountered difficulties with low levels of recombinant protein expression, and should benefit from an evidence based rational approach to synthetic gene design. Biotechnol. Bioeng. 2017;114: 492-502. © 2016 Wiley Periodicals, Inc.
[Mh] Termos MeSH primário: Códon
Engenharia Genética/métodos
Agricultura Molecular/métodos
Plantas Geneticamente Modificadas
[Mh] Termos MeSH secundário: Códon/genética
Códon/metabolismo
Plantas Geneticamente Modificadas/genética
Plantas Geneticamente Modificadas/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Codon)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160913
[St] Status:MEDLINE
[do] DOI:10.1002/bit.26183


  5 / 68 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27442628
[Au] Autor:Shahid N; Daniell H
[Ad] Endereço:Department of Biochemistry, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA.
[Ti] Título:Plant-based oral vaccines against zoonotic and non-zoonotic diseases.
[So] Source:Plant Biotechnol J;14(11):2079-2099, 2016 Nov.
[Is] ISSN:1467-7652
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The shared diseases between animals and humans are known as zoonotic diseases and spread infectious diseases among humans. Zoonotic diseases are not only a major burden to livestock industry but also threaten humans accounting for >60% cases of human illness. About 75% of emerging infectious diseases in humans have been reported to originate from zoonotic pathogens. Because antibiotics are frequently used to protect livestock from bacterial diseases, the development of antibiotic-resistant strains of epidemic and zoonotic pathogens is now a major concern. Live attenuated and killed vaccines are the only option to control these infectious diseases and this approach has been used since 1890. However, major problems with this approach include high cost and injectable vaccines is impractical for >20 billion poultry animals or fish in aquaculture. Plants offer an attractive and affordable platform for vaccines against animal diseases because of their low cost, and they are free of attenuated pathogens and cold chain requirement. Therefore, several plant-based vaccines against human and animals diseases have been developed recently that undergo clinical and regulatory approval. Plant-based vaccines serve as ideal booster vaccines that could eliminate multiple boosters of attenuated bacteria or viruses, but requirement of injectable priming with adjuvant is a current limitation. So, new approaches like oral vaccines are needed to overcome this challenge. In this review, we discuss the progress made in plant-based vaccines against zoonotic or other animal diseases and future challenges in advancing this field.
[Mh] Termos MeSH primário: Agricultura Molecular/métodos
Plantas/metabolismo
Vacinas
[Mh] Termos MeSH secundário: Administração Oral
Animais
Seres Humanos
Gado
Plantas/genética
Vacinas/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Vaccines)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170830
[Lr] Data última revisão:
170830
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160722
[St] Status:MEDLINE
[do] DOI:10.1111/pbi.12604


  6 / 68 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27263008
[Au] Autor:Hnatuszko-Konka K; Luchniak P; Wiktorek-Smagur A; Gerszberg A; Kowalczyk T; Gatkowska J; Kononowicz AK
[Ad] Endereço:Department of Genetics, Plant Molecular Biology and Biotechnology, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12/16, 90-237, Lodz, Poland. kath@biol.uni.lodz.pl.
[Ti] Título:The pharmaceutics from the foreign empire: the molecular pharming of the prokaryotic staphylokinase in Arabidopsis thaliana plants.
[So] Source:World J Microbiol Biotechnol;32(7):113, 2016 Jul.
[Is] ISSN:1573-0972
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Here, we present the application of microbiology and biotechnology for the production of recombinant pharmaceutical proteins in plant cells. To the best of our knowledge and belief it is one of few examples of the expression of the prokaryotic staphylokinase (SAK) in the eukaryotic system. Despite the tremendous progress made in the plant biotechnology, most of the heterologous proteins still accumulate to low concentrations in plant tissues. Therefore, the composition of expression cassettes to assure economically feasible level of protein production in plants remains crucial. The aim of our research was obtaining a high concentration of the bacterial anticoagulant factor-staphylokinase, in Arabidopsis thaliana seeds. The coding sequence of staphylokinase was placed under control of the ß-phaseolin promoter and cloned between the signal sequence of the seed storage protein 2S2 and the carboxy-terminal KDEL signal sequence. The engineered binary vector pATAG-sak was introduced into Arabidopsis thaliana plants via Agrobacterium tumefaciens-mediated transformation. Analysis of the subsequent generations of Arabidopsis seeds revealed both presence of the sak and nptII transgenes, and the SAK protein. Moreover, a plasminogen activator activity of staphylokinase was observed in the protein extracts from seeds, while such a reaction was not observed in the leaf extracts showing seed-specific activity of the ß-phaseolin promoter.
[Mh] Termos MeSH primário: Arabidopsis/genética
Arabidopsis/metabolismo
Metaloendopeptidases/biossíntese
Metaloendopeptidases/genética
Agricultura Molecular/métodos
Proteínas Recombinantes de Fusão/biossíntese
Proteínas Recombinantes de Fusão/genética
[Mh] Termos MeSH secundário: Agrobacterium tumefaciens/genética
Biotecnologia/métodos
Coenzimas
DNA Bacteriano/genética
Escherichia coli/genética
Perfilação da Expressão Gênica
Vetores Genéticos
Metaloendopeptidases/química
Plantas Geneticamente Modificadas
Regiões Promotoras Genéticas
Proteínas Recombinantes de Fusão/química
Sementes/genética
Sementes/metabolismo
Transgenes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Coenzymes); 0 (DNA, Bacterial); 0 (Recombinant Fusion Proteins); 0 (T-DNA); EC 3.4.24.- (Metalloendopeptidases); EC 3.4.24.29 (auR protein, Staphylococcus aureus)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170413
[Lr] Data última revisão:
170413
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160606
[St] Status:MEDLINE
[do] DOI:10.1007/s11274-016-2070-z


  7 / 68 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27155248
[Au] Autor:Chan HT; Xiao Y; Weldon WC; Oberste SM; Chumakov K; Daniell H
[Ad] Endereço:Department of Biochemistry, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA.
[Ti] Título:Cold chain and virus-free chloroplast-made booster vaccine to confer immunity against different poliovirus serotypes.
[So] Source:Plant Biotechnol J;14(11):2190-2200, 2016 Nov.
[Is] ISSN:1467-7652
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The WHO recommends complete withdrawal of oral polio vaccine (OPV) type 2 by April 2016 globally and replacing with at least one dose of inactivated poliovirus vaccine (IPV). However, high-cost, limited supply of IPV, persistent circulating vaccine-derived polioviruses transmission and need for subsequent boosters remain unresolved. To meet this critical need, a novel strategy of a low-cost cold chain-free plant-made viral protein 1 (VP1) subunit oral booster vaccine after single IPV dose is reported. Codon optimization of the VP1 gene enhanced expression by 50-fold in chloroplasts. Oral boosting of VP1 expressed in plant cells with plant-derived adjuvants after single priming with IPV significantly increased VP1-IgG1 and VP1-IgA titres when compared to lower IgG1 or negligible IgA titres with IPV injections. IgA plays a pivotal role in polio eradication because of its transmission through contaminated water or sewer systems. Neutralizing antibody titres (~3.17-10.17 log titre) and seropositivity (70-90%) against all three poliovirus Sabin serotypes were observed with two doses of IPV and plant-cell oral boosters but single dose of IPV resulted in poor neutralization. Lyophilized plant cells expressing VP1 stored at ambient temperature maintained efficacy and preserved antigen folding/assembly indefinitely, thereby eliminating cold chain currently required for all vaccines. Replacement of OPV with this booster vaccine and the next steps in clinical translation of FDA-approved antigens and adjuvants are discussed.
[Mh] Termos MeSH primário: Cloroplastos/imunologia
Vacina Antipólio Oral/imunologia
[Mh] Termos MeSH secundário: Doenças Transmissíveis
Seres Humanos
Agricultura Molecular
Vacinação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Poliovirus Vaccine, Oral)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170830
[Lr] Data última revisão:
170830
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160508
[St] Status:MEDLINE
[do] DOI:10.1111/pbi.12575


  8 / 68 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27049632
[Au] Autor:Tschofen M; Knopp D; Hood E; Stöger E
[Ad] Endereço:Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, 1190 Vienna, Austria; email: eva.stoeger@boku.ac.at.
[Ti] Título:Plant Molecular Farming: Much More than Medicines.
[So] Source:Annu Rev Anal Chem (Palo Alto Calif);9(1):271-94, 2016 Jun 12.
[Is] ISSN:1936-1335
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Plants have emerged as commercially relevant production systems for pharmaceutical and nonpharmaceutical products. Currently, the commercially available nonpharmaceutical products outnumber the medical products of plant molecular farming, reflecting the shorter development times and lower regulatory burden of the former. Nonpharmaceutical products benefit more from the low costs and greater scalability of plant production systems without incurring the high costs associated with downstream processing and purification of pharmaceuticals. In this review, we explore the areas where plant-based manufacturing can make the greatest impact, focusing on commercialized products such as antibodies, enzymes, and growth factors that are used as research-grade or diagnostic reagents, cosmetic ingredients, and biosensors or biocatalysts. An outlook is provided on high-volume, low-margin proteins such as industrial enzymes that can be applied as crude extracts or unprocessed plant tissues in the feed, biofuel, and papermaking industries.
[Mh] Termos MeSH primário: Produtos Biológicos/metabolismo
Agricultura Molecular
Plantas/metabolismo
[Mh] Termos MeSH secundário: Anticorpos/metabolismo
Enzimas/biossíntese
Peptídeos e Proteínas de Sinalização Intercelular/biossíntese
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies); 0 (Biological Products); 0 (Enzymes); 0 (Intercellular Signaling Peptides and Proteins)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160407
[St] Status:MEDLINE
[do] DOI:10.1146/annurev-anchem-071015-041706


  9 / 68 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26873071
[Au] Autor:Juarez P; Virdi V; Depicker A; Orzaez D
[Ad] Endereço:Department of Plant Systems Biology, VIB, Gent, Belgium.
[Ti] Título:Biomanufacturing of protective antibodies and other therapeutics in edible plant tissues for oral applications.
[So] Source:Plant Biotechnol J;14(9):1791-9, 2016 Sep.
[Is] ISSN:1467-7652
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Although plant expression systems used for production of therapeutic proteins have the advantage of being scalable at a low price, the downstream processing necessary to obtain pure therapeutic molecules is as expensive as for the traditional Chinese hamster ovary (CHO) platforms. However, when edible plant tissues (EPTs) are used, there is no need for exhaustive purification, because they can be delivered orally as partially purified formulations that are safe for consumption. This economic benefit is especially interesting when high doses of recombinant proteins are required throughout the treatment/prophylaxis period, as is the case for antibodies used for oral passive immunization (OPI). The secretory IgA (SIgA) antibodies, which are highly abundant in the digestive tract and mucosal secretions, and thus the first choice for OPI, have only been successfully produced in plant expression systems. Here, we cover most of the up-to-date examples of EPT-produced pharmaceuticals, including two examples of SIgA aimed at oral delivery. We describe the benefits and drawbacks of delivering partially purified formulations and discuss a number of practical considerations and criteria to take into account when using plant expression systems, such as subcellular targeting, protein degradation, glycosylation patterns and downstream strategies, all crucial for improved yield, high quality and low cost of the final product.
[Mh] Termos MeSH primário: Anticorpos/metabolismo
Agricultura Molecular/métodos
Plantas Comestíveis/metabolismo
[Mh] Termos MeSH secundário: Seres Humanos
Imunização/métodos
Plantas Comestíveis/genética
Plantas Geneticamente Modificadas/genética
Plantas Geneticamente Modificadas/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170901
[Lr] Data última revisão:
170901
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160214
[St] Status:MEDLINE
[do] DOI:10.1111/pbi.12541


  10 / 68 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26773389
[Au] Autor:Marsian J; Lomonossoff GP
[Ad] Endereço:Department of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, United Kingdom. Electronic address: johanna.marsian@jic.ac.uk.
[Ti] Título:Molecular pharming - VLPs made in plants.
[So] Source:Curr Opin Biotechnol;37:201-206, 2016 Feb.
[Is] ISSN:1879-0429
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Plant-based expression offers a safe, inexpensive and potentially limitless way to produce therapeutics in a quick and flexible manner. Plants require only simple inorganic nutrients, water, carbon dioxide and sunlight for efficient growth. Virus-like particles (VLPs) are convincing look-alikes of viruses but without carrying infectious genomic material. However, they can still elicit a very potent immune response which makes them ideal vaccine candidates. In this review the different methods of plant expression are described together with the most recent developments in the field of transiently-expressed plant-made VLPs.
[Mh] Termos MeSH primário: Agricultura Molecular
Plantas Geneticamente Modificadas/metabolismo
Vírion/metabolismo
[Mh] Termos MeSH secundário: Expressão Gênica
Plantas Geneticamente Modificadas/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Em] Mês de entrada:1607
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160117
[St] Status:MEDLINE



página 1 de 7 ir para página                  
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde